FREQ Stock Overview
As of November 3, 2023, Frequency Therapeutics, Inc. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Frequency Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.98 |
| 52 Week High | US$279.50 |
| 52 Week Low | US$9.15 |
| Beta | 0.77 |
| 1 Month Change | -0.10% |
| 3 Month Change | -58.68% |
| 1 Year Change | -87.52% |
| 3 Year Change | -98.71% |
| 5 Year Change | n/a |
| Change since IPO | -97.81% |
Recent News & Updates
Recent updates
Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?
Jan 01
Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?
Jan 19Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year
Aug 18Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?
Jul 31Frequency Therapeutics (FREQ) Investor Presentation - Slideshow
Jun 18Frequency Therapeutics: A Look At What's Next After A Disappointing Data Readout
Apr 21Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be
Apr 04We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn
Mar 15If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns
Jan 22Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?
Dec 27Frequency Therapeutics to host investor event in early January next year
Dec 18How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?
Dec 10Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 19Frequency Therapeutics EPS beats by $0.16, beats on revenue
Nov 16Frequency Therapeutics Is An Interesting Speculative Play Ahead Of Phase 2 Results
Nov 09Shareholder Returns
| FREQ | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 29.1% | -3.6% | -2.4% |
| 1Y | -87.5% | -2.7% | 23.3% |
Return vs Industry: FREQ underperformed the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: FREQ underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| FREQ volatility | |
|---|---|
| FREQ Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FREQ's share price has been volatile over the past 3 months.
Volatility Over Time: FREQ's weekly volatility has decreased from 21% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 47 | David Lucchino | www.frequencytx.com |
As of November 3, 2023, Frequency Therapeutics, Inc. was acquired by Korro Bio, Inc., in a reverse merger transaction. Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person’s innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue.
Frequency Therapeutics, Inc. Fundamentals Summary
| FREQ fundamental statistics | |
|---|---|
| Market cap | US$547.27m |
| Earnings (TTM) | -US$59.31m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.2x
P/E RatioIs FREQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FREQ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$42.02m |
| Gross Profit | -US$42.01m |
| Other Expenses | US$17.30m |
| Earnings | -US$59.31m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.62 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did FREQ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/11/05 11:57 |
| End of Day Share Price | 2023/11/03 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Frequency Therapeutics, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Daniil Gataulin | Chardan Capital Markets, LLC |